What's New in Biotech? Nasdaq Explores the Latest in the Sector's Innovation and Investment

Nasdaq has long been the home for biotech companies, and this past January, National Biotechnology Month proved no different. The sector was active with five healthcare companies raising $800 million in the first few weeks of 2025 alone. "The momentum we're seeing in biotech listings reflects the sector's continued evolution and strength," said Jordan Saxe, Head of Healthcare Listings at Nasdaq. "We're witnessing significant advances across multiple therapeutic areas, particularly in treatments for obesity and inflammatory conditions. Later-stage data in these sub-sectors has produced more mature assets, inspiring investor confidence and further advancement."

Nasdaq's connection to the biotech sector dates to 1976 when it listed Genentech—the first public biotech company—marking the beginning of a relationship that would shape the industry's development. Nasdaq also created the Nasdaq Biotechnology Index (NBI) on November 1, 1993, which is comprised of dynamic and innovative biotech companies listed on the exchange. The NBI is currently up 4.9% year-to-date and indicates that large-cap biotech is leading the charge for growth.

This January, ahead of the 43rd Annual JP Morgan Healthcare Conference, which is seen as a prominent venue to share ideas, forge partnerships, and explore groundbreaking work across the healthcare sector, Nasdaq hosted Invesco and companies of the Nasdaq Biotech Index for a bell-ringing ceremony at the Nasdaq Entrepreneurial Center in San Francisco.

Nasdaq Biotech Index Opening Bell at the Nasdaq Entrepreneurial Center in Celebration of the 43rd Annual JP Morgan Healthcare Conference

The State of Biotech in 2025

The growth trajectory of the biotech industry has been particularly notable over the last decade. Since 2015, Nasdaq has overseen a 57% increase in healthcare companies, from 634 to 994. According to BioSpace, investment in biopharma (biotech + pharmaceutical companies) in 2024 increased by 11% from $23.3 billion to $26 billion. Furthermore, HSBC’s 2024 annual venture healthcare report shows that investment is focused on early stage mega-rounds, with the most relevant therapeutic topics, like AI and weight-loss, gaining traction earlier on than other sub-sectors. 

Following last month’s J.P. Morgan Healthcare Conference, the state of biotech in 2025 came into clearer focus.

"We're seeing strong confidence from early-stage venture capital firms, while public market investors are taking a more measured approach.” Saxe said, “I expect 2025 to be a productive year in the biotech space, especially in terms of prospective M&A as one of the leading avenues of sector investment."

Trends Affecting the Industry

Saxe pointed to momentum in therapeutic areas including weight loss treatments, where the clinical success of GLP-1 medications is spurring a wave of innovation, as well as I&I (immunology and inflammation), in which a new class of drugs are approaching cancers and relevant conditions with great efficacy. The radio-pharma sector is also gaining traction, rapidly improving the accuracy of cancer treatments, and medical devices are making a notable return to public markets after several years of lowered activity. 

The integration of artificial intelligence in healthcare is also promising, particularly in drug discovery. Companies leveraging AI for cancer vaccines and other therapeutic applications are finding new ways to innovate, marking what Saxe describes as "a new wave of healthcare, where hyper-scaling compute technology enables better informed, accurate decisions earlier in the development process."

Investor interest remains robust, particularly for companies that have demonstrated promising results in clinical trials. "Investors are focusing on high-quality, later-stage assets," Saxe explained. "Whether it's a company in advanced development stages or one with a drug derivative showing strong efficacy and safety data, mature enterprises are attracting significant attention.” This is also true for the sector’s IPO market. Compared to 2021, when many biotech IPOs were pre-clinical, sector IPOs today are more likely to be at the matured clinical stage, anticipating a significant data readout and promising indication post-listing.

Looking Ahead

Looking ahead, the pipeline for biotech listings remains strong, with more than 25 potential biotech IPOs readying to enter the markets. Currently, 28 healthcare companies have filed for public listings in the U.S, with more on the horizon.

"Market conditions are increasingly favorable for biotech companies," Saxe said. "There's substantial 'dry powder' investment capital available, and we're seeing unprecedented levels of scientific innovation. Companies demonstrating that they can truly transform patient care are going to draw a lot of interest."

Much like the mapping of the human genome fostered an ecosystem of innovative companies, the current wave of AI integration and computational advances is creating new possibilities for healthcare solutions, Saxe added.

Year-to-date, healthcare has been the top performing sector in the market. For Nasdaq, which has helped take more than 650 healthcare companies public since 2015, including the recent listings of Ascentage Pharma and Aardvark Therapeutics.. Healthcare companies that pioneer new treatments and technologies are continuing to choose Nasdaq, an exchange that has championed their sector for half a century, offering unparallelled access to public capital, and the opportunity to improve countless lives at the forefront of innovation. 

Learn more about Nasdaq Listed Biotech Companies

Information is provided for educational purposes only. Nasdaq does not recommend or endorse any securities offering, index, industry or sector.  Nothing contained herein should be construed as investment advice; you are urged to undertake your own due diligence and carefully evaluate any company, industry or sector before investing.  ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.